

October 26, 2026

To our friends in the systemic mastocytosis and mast cell disease community,

Last year, Sanofi announced its acquisition of Blueprint Medicines to accelerate our mission of improving the lives of people with systemic mastocytosis (SM). I'm excited to update you on our integration into Sanofi and how it'll help us further advance patient care, building on our foundational efforts to-date.

A core team from Blueprint will continue at Sanofi

For the past year, we've been operating as Blueprint Medicines, a Sanofi company. In the coming months, Blueprint colleagues and I will formally join Sanofi, working alongside Sanofi colleagues as one integrated team. I've focused on SM since the early stages of our clinical trials, and I'm excited to keep leading a group of exceptional team members dedicated to this disease. A core set of individuals who have contributed to our efforts in SM will continue this work at Sanofi.

Sanofi will further Blueprint's long-term commitment in SM

As we look to our next chapter at Sanofi, we feel a deep sense of responsibility to carry our work forward on behalf of the SM community who have contributed to our efforts, including all the patients, study investigators, and medical center staff who took part in our clinical trials. I also want to recognize every Blueprint team member who has been part of our journey over the past 15+ years for their dedication to advance research, clinical development, and patient care in SM.

Sanofi will build on Blueprint's efforts with complementary capabilities

What's been most gratifying about working with the Sanofi team is their commitment to understand the needs of the SM community, uphold our "patients first" culture and help us benefit more patients, faster than we could alone. As I've connected with new colleagues, it's become increasingly clear how we can continue growing our impact at Sanofi. The company has a 40-year legacy in rare diseases, focused on advancing treatment breakthroughs, applying science in new ways, and shaping how care is delivered by bringing together patients, caregivers, advocates, healthcare providers, and policymakers. We're actively identifying how we can best apply Sanofi's global rare disease capabilities to further elevate clinical outcomes in SM.

Sanofi aspires to continue advancing SM care

Building on more than 15 years of innovation in SM, we remain committed to collaborating with you to accelerate our impact. Our achievements to-date wouldn't have been possible without the close partnership of a dedicated community of patients, caregivers, healthcare providers, clinical researchers, and advocacy groups, and we want to express our deepest gratitude for all your contributions. As part of Sanofi, we aim to continue transforming care for as many patients as possible.

Wishing you all the best,



Maria Roche

Head of SM Clinical Research at Blueprint Medicines, a Sanofi company
Global SM Leader at Sanofi